UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the
Registrant
x
Filed by a
Party other than the Registrant
¨
Check the
appropriate box:
|
|
|
|
|
¨
|
|
Preliminary Proxy Statement
|
|
|
¨
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
¨
|
|
Definitive Proxy Statement
|
|
|
x
|
|
Definitive Additional Materials
|
|
|
¨
|
|
Soliciting Material Pursuant to Rule 14a-12
|
|
SUN HEALTHCARE GROUP, INC.
|
(Name of Registrant as Specified In Its Charter)
|
|
|
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
|
|
Payment of Filing Fee (Check the appropriate box):
|
|
|
x
|
|
No fee required.
|
|
|
¨
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
|
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
|
|
|
(5)
|
|
Total fee paid:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¨
|
|
Fee paid previously with preliminary materials:
|
|
|
¨
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the form or schedule and the date of its filing.
|
|
|
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
|
|
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
|
|
|
|
|
(3)
|
|
Filing Party:
|
|
|
|
|
|
|
|
(4)
|
|
Date Filed:
|
|
|
|
|
|
SUN HEALTHCARE GROUP, INC.
18831 Von Karman, Suite 400
Irvine, California 92612
SUPPLEMENT TO PROXY STATEMENT
FOR THE SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON SEPTEMBER 5, 2012
This is a supplement to the proxy
statement dated July 24, 2012 (the proxy statement) of Sun Healthcare Group, Inc. (Company, Sun, we, our and us) that was mailed to you in connection with the solicitation
of proxies for use at the special meeting of stockholders to be held on Wednesday, September 5, 2012 at the Hilton Irvine/Orange County Airport, located at 18800 MacArthur Blvd., Irvine, California 92612, at 9:00 a.m., Pacific Time. The purpose
of the special meeting is to consider and vote upon the following proposals
|
|
|
adoption of the Agreement and Plan of Merger, dated June 20, 2012, by and among Genesis HealthCare LLC (Genesis), Jam Acquisition LLC,
a wholly owned subsidiary of Genesis (Merger Sub), and Sun, as such agreement may be amended from time to time (the merger agreement);
|
|
|
|
approval of the adjournment of the special meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the
special meeting to adopt the merger agreement; and
|
|
|
|
approval on an advisory (non-binding) basis of the golden parachute compensation arrangements that may be paid or become payable to our
named executive officers in connection with the merger and the agreements and understandings pursuant to which such compensation may be paid or become payable.
|
Our board of directors previously established July 19, 2012 as the record date for the determination of stockholders entitled to
notice of and to vote at the special meeting.
If you have not already submitted a proxy for use at the special meeting, you
are urged to do so promptly. No action in connection with this supplement to the proxy statement is required by any stockholder who has previously delivered a proxy and who does not wish to revoke or change that proxy. Information about voting or
revoking a proxy appears on pages 11 through 13 of the proxy statement.
Litigation Relating to the Merger
As described in the proxy statement, between June 27, 2012 and July 16, 2012, Sun, the members of our board of directors,
Genesis and Merger Sub were named as defendants in connection with the transactions contemplated by the merger agreement in four separate purported class action lawsuits that were filed in the Superior Court of the State of California, County of
Orange and in a purported class action lawsuit filed in the
Court of Chancery of the State of Delaware. The Delaware lawsuit was subsequently dismissed without prejudice and the Delaware plaintiff then filed a complaint in the Superior Court of the State
of California, County of Orange on July 31, 2012. On August 3, 2012, the parties to the initial four California lawsuits executed a stipulation to consolidate the first four California actions, including any subsequently filed actions with
similar allegations relating to the transaction (including the action filed on July 31, 2012). The amended complaint filed in the purported consolidated action alleges, among other things, that our directors breached their fiduciary duties to
our stockholders in entering into the merger agreement pursuant to an unfair process, and that we, Genesis and Merger Sub aided and abetted the alleged breaches of fiduciary duties. In addition, the complaint filed on July 31, 2012 alleges that
the preliminary proxy statement filed by Sun on July 12, 2012 omits or misrepresents material information. The lawsuits seek, among other things, to enjoin consummation of the merger.
On August 29, 2012, the plaintiffs and defendants in the consolidated action entered into a memorandum of understanding in which
they agreed on the terms of a proposed settlement of the lawsuits, which would include the dismissal with prejudice of all claims against all of the defendants. The proposed settlement is subject to customary conditions, including the execution of
an appropriate stipulation of settlement and court approval following notice to Suns stockholders. In the event that the parties enter into a stipulation of settlement, a hearing will be scheduled at which the court will consider the fairness,
reasonableness and adequacy of the settlement. There can be no assurance that the parties will ultimately enter into a stipulation of settlement, that the court will approve any proposed settlement, or that any eventual settlement will be under the
same terms as those contemplated by the memorandum of understanding. The proposed settlement will not affect the amount of the merger consideration that our stockholders are entitled to receive in the merger.
The defendants deny all liability with respect to the facts and claims alleged in the lawsuits and specifically deny that any
supplemental disclosure was or is required under any applicable rule, statute, regulation or law. However, to minimize the expense of defending the lawsuits, to avoid the risk of delaying or adversely affecting the merger and the related
transactions, and to provide additional information to our stockholders at a time and in a manner that would not cause any delay of the special meeting or the merger, we have determined to provide the supplemental disclosures below, as contemplated
by the memorandum of understanding and the proposed settlement.
Additional Disclosures
As contemplated by the proposed settlement, we are providing certain additional disclosures that are supplemental to those contained in
the proxy statement previously mailed to you. This supplemental information should be read in conjunction with the proxy statement, which we urge you to read in its entirety. As noted above, none of the defendants has admitted wrongdoing of any
kind, including but not limited to inadequacies in any disclosure, the materiality of any disclosure that the plaintiffs contend should have been made, any breach of any fiduciary duty, or aiding or abetting any of the foregoing.
2
The following additional disclosures (changes marked with new text underlined and deleted
text marked with strikethrough) amend and supplement the information provided in the proxy statement:
PROPOSAL NO. 1 ADOPTION OF
THE MERGER AGREEMENT Background of the Merger
(page 20 of the proxy statement)
The
following paragraph is inserted as a new paragraph immediately following the third (3
rd
) paragraph under the heading Background of the Merger:
On
March 31, 2011, at a meeting of the executive committee of our board of directors, Mr. Mathies presented to the executive committee materials summarizing several strategic opportunities that had been presented to the Company, including a
potential business combination transaction with Genesis and two other proposed acquisitions with Sun as the potential buyer.
PROPOSAL
NO. 1 ADOPTION OF THE MERGER AGREEMENT Background of the Merger
(page 20 of the proxy statement)
The twelfth (12
th
) paragraph beneath the heading Background of the Merger is revised as follows:
On December 2, 2011, at a special meeting of our board of directors, Mr. Mathies updated the board regarding the status of discussions regarding a potential business combination transaction with
Genesis. Representatives of MTS discussed with the board the companys status as an independent company, the challenges facing the company, including the increasingly difficult reimbursement and operating environment, and an overview of a
possible transaction with Genesis. Representatives of MTS also reviewed with the board the various possible strategic alternatives to a business combination with Genesis, including various growth alternatives, such as a range of small to large
acquisitions, including in partnership with one or more real estate companies, as well as sales of individual business units, a sale of the whole company to one or more private equity buyers or a strategic buyer or a merger with a strategic buyer.
The board discussed the various alternatives, including the low likelihood of interest from a private equity buyer
due to (i) the Companys existing significant lease-adjusted leverage and limited (if any) incremental debt capacity and
(ii) MTS historical discussions with private equity funds capable of executing a private equity transaction with Sun and their lack of interest in skilled nursing or any such transaction and the failure of any such fund to express
interest in a transaction to Company management either before or after the publication of the CMS Final Rule,
and the low likelihood of a more attractive stock or cash proposal from another strategic buyer
due to the limited number of
potential strategic buyers with a desire to receive Sun equity in a transaction or the ability to finance a transaction, current and prospective uncertainty for the Companys reimbursement environment and the unique ability of Genesis to
finance a transaction, successfully integrate the Company and achieve disproportionate (relative to other parties) operational and strategic flexibility from a transaction with the Company
. At the conclusion of this meeting, the board authorized
management and MTS to continue their
3
discussions with Genesis regarding a potential framework for a transaction, but to counter Genesis offer of a 40%/60% equity split with a 45%/55% equity split. Subsequent to the board
meeting, this counteroffer was conveyed by a representative of MTS to a representative of Genesis investors and in their discussions, they agreed to coordinate a meeting of the parties to discuss this and other matters in January 2012.
PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT Background of the
(page 20 of the proxy statement)
The following paragraph is inserted as a new paragraph immediately following the twentieth (20
th
) paragraph under the heading Background of the
Merger:
On February 27, 2012, at a regularly scheduled meeting of our board of directors, Mr. Mathies
updated the board on the status of managements discussions with Genesis, including Genesis decision not to pursue a stock-for-stock merger transaction with the Company and its interest in an all-cash acquisition of the Company. As the
board remained interested in pursuing a transaction with Genesis given the potential attractiveness of a cash transaction relative to the Companys standalone prospects, at the conclusion of the meeting, the board authorized management to
continue discussions with Genesis regarding a potential business combination transaction.
PROPOSAL NO. 1 ADOPTION OF THE MERGER
AGREEMENT Opinion of Our Financial Advisor
Sun Valuation Analysis
(page 33 of the proxy statement)
The third
(3
rd
) paragraph under the heading Opinion of
Our Financial Advisor and the sub-heading Sun Valuation Analysis is revised as follows:
For purposes of its
analyses, MTS Securities calculated Suns equity market value (EMV), immediately prior to the announcement of the merger to be approximately $160 million, based on approximately 26.889 million shares of Sun common stock
outstanding as of June 18, 2012, calculated using the treasury stock method and the closing price per share of Sun common stock on June 18, 2012. MTS Securities also calculated Suns enterprise value (EV) and adjusted
enterprise value (AEV), in each case prior to the announcement of the merger, under two different scenarios. In the first scenario, certain obligations of Sun relating to workers compensation obligations secured by letters of
credit in the amount of approximately $55 million (the L/C Obligations) were excluded from the definition of debt used in such calculations, consistent with the presentation thereof on Suns balance sheet. In the second scenario,
the L/C Obligations were included in the definition of debt used in such calculations in order to provide a comparable presentation of such equity value with the peer company group identified below under the caption Selected Public
Companies Analysis, who generally fund such workers compensation obligations with cash balances, thereby reducing their associated equity value. MTS Securities calculated (i) Suns implied EV (for the purposes of this analysis,
implied EV equates to implied EMV, plus debt, less cash and cash equivalents) to be approximately $205 million when the L/C Obligations were excluded from debt and approximately $260 million when the L/C Obligations were included in debt, and
(ii) Suns implied AEV (for the purposes of this analysis, implied
4
AEV equates to implied EV, plus capitalized rent (using an industry-standard 8.0x multiple)), to be approximately $1.397 billion when the L/C Obligations were excluded from debt and approximately
$1.452 billion when the L/C Obligations were included in debt.
Due to their limited expected value in future periods, MTS did not assign any additional value to the Companys net operating loss carry-forwards in MTS analyses.
PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT Opinion of Our Financial Advisor
Selected Public Companies
Analysis
(page 34 of the proxy statement)
The last paragraph under the heading Opinion of Our Financial
Advisor and the sub-heading Selected Public Companies Analysis is revised as follows:
The selected public
companies analysis showed that, based on the estimates and assumptions used in the analysis, the implied ranges of values of Suns common stock based on the derived multiples of 2012 AEV/EBITDAR
(6.2x to 6.5x)
were $6.26 to 9.30 per
share (excluding the L/C Obligations from debt) and $4.21 to $7.25 per share (including the L/C Obligations as debt), and the implied ranges of value of Suns common stock based on the derived multiples of 2012 EV/EBITDA
(2.7x to 4.7x
including L/C Obligations as debt and 3.5x-4.7x excluding L/C Obligations as debt)
were $6.43 to $12.17 per share (excluding the L/C Obligations from debt) and $6.55 to $10.12 (including the L/C Obligations as debt).
PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT Opinion of Our Financial Advisor
Sum-of-the-Parts Analysis
(page 35 of the proxy statement)
The disclosure under the heading Opinion of Our Financial Advisor and
the sub-heading Sum-of-the-Parts Analysis is revised in its entirety as follows:
MTS Securities performed a
sum-of-the-parts valuation of each of Suns business units in order to derive an implied per share equity value for Sun. MTS Securities examined and valued Suns inpatient services business, Suns rehabilitation therapy services
business, Suns hospice business and Suns medical staffing services business. MTS Securities utilized a multiples-based valuation methodology based on the trading multiples
and/or acquisition multiples
of selected comparable
publicly traded
companies; this valuation technique does not
specifically
account for any control premiums or takeover premiums or synergies, but rather is based strictly on standalone valuations. MTS Securities specifically
utilized the ratio of Sun managements estimated post-corporate EBITDA (calculated as total EBITDA of $
143.5
145.3
million less managements estimated 2012 allocation for corporate overhead of $65.8 million) for
calendar year 2012 in its multiple-based methodology analysis.
The pre- and post-corporate EBITDA amounts, range of trading multiples and implied enterprise value utilized by MTS in its analysis for each of Suns business units are set forth
below ($ in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Unit
|
|
Pre-
Corporate
EBITDA
|
|
|
Post-
Corporate
EBITDA
|
|
|
Selected
Trading
Multiple
Ranges
|
|
Implied
Enterprise
Values
|
Inpatient Services
|
|
$
|
111.9
|
|
|
$
|
52.4
|
|
|
2.5x 3.5x
|
|
$131.0 $183.5
|
Rehabilitation Therapy Services
|
|
|
9.1
|
|
|
|
6.0
|
|
|
4.0x 6.0x
|
|
$24.2 $36.2
|
Hospice
|
|
|
17.5
|
|
|
|
16.1
|
|
|
7.0x 9.0x
|
|
$83.7 $103.0
|
Medical Staffing Services
|
|
|
6.8
|
|
|
|
4.9
|
|
|
6.0x 8.0x
|
|
$29.3 $39.1
|
5
MTS Securities based its valuation analysis of (i) the inpatient services business on
the trading and/or acquisition multiples of certain selected comparable companies operating in the inpatient services market, (ii) the rehabilitation therapy services business on the trading and/or acquisition multiples of certain selected
comparable
publicly traded
companies operating in the rehabilitation therapy services market, (iii) the hospice business on the trading and/or acquisition multiples of selected comparable
publicly traded
companies operating in the hospice market and (iv) the medical services staffing business on the trading and/or acquisition multiples of certain selected comparable
publicly traded
companies operating in the medical services
staffing market. None of the foregoing comparable companies is identical to Sun on a standalone basis, and with the exception of the medical services staffing business, there were limited
(and in some instances, no)
comparable publicly traded
companies for MTS to use in its analysis, further adding to the subjective nature of the analysis. Additionally, the analysis does not take into account (x) timing and execution risk for monetizing these business units, the availability of
financing for each such transaction and the potential transaction costs, and (y) with exception of the hospice business unit
(for which marginal tax costs of 40% were assumed)
, the tax implications that may arise through an attempt to
monetize these business units. Using these sum-of-the-parts valuation analyses for each of Suns business units, MTS Securities estimated the implied total equity value of Sun
(using the composite enterprise value of the four business
segments net of debt and cash)
to be between $8.31 and $11.79 per share when excluding the L/C Obligations from debt, and between $6.27 and $9.75 per share when including the L/C Obligations as debt. MTS Securities compared these per share value
ranges to the merger consideration of $8.50 per share.
PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT Opinion of Our
Financial Advisor
Discounted Future Share Price Value Analysis
(page 36 of the proxy statement)
The disclosure under the heading Opinion of Our Financial Advisor and the sub-heading Discounted Future Share Price Value Analysis is revised in its entirety as follows:
MTS Securities performed a discounted future share price value analysis on Sun based on the Sun projections from 2013 through
2015 using a range of EBITDA multiples ranging from 2.58x to 3.60x (based on Suns current trading
multiple implied by the Sun projections for 2012
values
and its average EV/EBITDA multiple prior to the April 28,
2011 CMS-proposed Medicare rates) applied to Suns future earnings.
The
6
projections utilized by MTS in this analysis were the same Sun projections set forth above under Projected Financial Information.
The per share values calculated were
discounted back to December 31, 2012 using a discount rate of 10.0%, representing Suns historical weighted average cost of capital
(calculated with a Sun market beta of 1.9, risk free rate of 1.2% based on U.S. Treasury yields and
market risk premium of 6.7% according to published Ibbotson figures)
. This analysis was performed using both Sun managements base case projections as well as Sun managements upside case projections from 2013 through 2015. This
analysis resulted in implied ranges of values per share of Sun common stock as set forth below:
|
|
|
|
|
|
|
L/C Obligations Excluded from Debt
|
|
L/C Obligations Included in Debt
|
Management Base Case
|
|
$5.72-$9.09 per share
|
|
$5.55-$8.79 per share
|
Management Upside Case
|
|
$6.13-$10.10 per share
|
|
$6.07-$9.92 per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
L/C Obligations Excluded from Debt
|
|
L/C Obligations Included in Debt
|
|
|
2013
|
|
2014
|
|
2015
|
|
2013
|
|
2014
|
|
2015
|
Management Base Case
|
|
$5.72-$8.26
|
|
$6.39-$9.01
|
|
$6.58-$9.09
|
|
$5.55-$7.61
|
|
$6.46-$8.58
|
|
$6.75-$8.79
|
Management Upside Case
|
|
$6.13-$8.83
|
|
$7.05-$9.88
|
|
$7.33-$10.10
|
|
$6.07-$8.26
|
|
$7.27-$9.57
|
|
$7.67-9.92
|
PROPOSAL NO. 1 ADOPTION OF THE MERGER AGREEMENT Opinion of Our Financial Advisor
General
(page 36 of the proxy statement)
The last paragraph under the heading Opinion of Our
Financial Advisor and the sub-heading General is revised as follows:
MTS and its affiliates, as part of
their investment banking business, are continually engaged in performing financial analyses with respect to healthcare businesses and their capitalization in connection with mergers and acquisitions, private placements and other transactions as well
as for corporate and other purposes. In the ordinary course of these activities, affiliates of MTS may at any time hold long or short positions, and may trade or otherwise effect transactions in debt or equity securities or loans of Sun, Genesis or
certain of their respective affiliates. As noted above, MTS acted as financial advisor to Sun in connection with, and participated in certain of the negotiations leading to, the merger agreement. In addition, during the two years prior to the date
of the MTS opinion, MTS provided investment banking and financial advisory services to Sun and received fees in connection with such services, including transaction-based fees and an ongoing
$75,000
quarterly retainer. Such services during
such period have also included acting as financial advisor to the former parent of Sun in connection with its 2010 restructuring and separation of its real estate assets and operating assets into Sabra Health Care REIT, Inc. and Sun, respectively,
for which MTS received fees equal to $9.6 million,
and acting as
7
financial advisor to Sun in connection with
its 2011 acquisition of Harbinger Hospice and
its 2010 acquisition of Countryside Hospice Care, Inc.
, for which acquisitions MTS did not
receive any transaction-based fees beyond its quarterly retainer
. MTS and its affiliates may also provide investment banking services to Sun and Genesis in the future, and would expect to receive fees for the rendering of such services. During
the two year period prior to the date of the MTS opinion, no material relationship existed between MTS or any of its affiliates and Genesis or any of its affiliates pursuant to which compensation was received by MTS or its affiliates.
Other Matters
Although
not relied upon by MTS Securities for purposes of the MTS opinion, MTS Securities also performed a discounted future share price value analysis on Sun based on the Sun projections from 2013 through 2015 using a range of EBITDAR multiples ranging
from 6.14x to 6.28x (based on Suns current trading multiples implied by 2012 analyst consensus and internal management EBITDAR projections). As with the discounted future share price value analysis performed by MTS Securities using EBIDTA
multiples as described above, the per share values calculated were discounted back to December 31, 2012 using a discount rate of 10.0%, representing Suns historical weighted average cost of capital (calculated with a Sun market beta of
1.9, risk free rate of 1.2% based on U.S. Treasury yields and market risk premium of 6.7% according to published Ibbotson figures). This analysis was performed using both Sun managements base case projections as well as Sun managements
upside case projections from 2013 through 2015. This analysis resulted in implied ranges of values per share of Sun common stock as set forth below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
L/C Obligations Excluded from Debt
|
|
L/C Obligations Included in Debt
|
|
|
2013
|
|
2014
|
|
2015
|
|
2013
|
|
2014
|
|
2015
|
Management Base Case
|
|
$5.96-$7.01
|
|
$7.55-$8.55
|
|
$8.00-$8.94
|
|
$5.94-$7.04
|
|
$7.64-$8.69
|
|
$8.14-$9.13
|
Management Upside Case
|
|
$6.94-$8.01
|
|
$8.99-$10.01
|
|
$9.64-$10.60
|
|
$6.95-$8.08
|
|
$9.12-$10.21
|
|
$9.84-$10.86
|
Regulatory Approvals
As previously announced, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on August 8, 2012. The closing of the transaction remains subject to
other customary conditions, as described more fully beginning on page 57 of the proxy statement.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements in this supplement and the documents to which we refer you in this
supplement contain forward-looking information as that term is defined by the Private Securities Litigation Reform Act of 1995, we which we refer to as the Act, and the federal securities laws. Any statements that do not relate to
historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include information concerning possible or assumed future results of operations of Sun,
8
the expected litigation settlement, the expected completion and timing of the merger and other information relating to the merger. You can identify some of the forward-looking statements by the
use of forward-looking words such as anticipate, believe, plan, estimate, expect, intend, should, may and other similar expressions, although not all
forward-looking statements contain these identifying words.
In addition to other factors and matters contained or
incorporated in this document, we believe the following factors could cause actual results to differ materially from those discussed in the forward-looking statements:
|
|
|
risks that the regulatory approvals required to be completed under the merger agreement will not be obtained in a timely manner or at all;
|
|
|
|
the inability to complete the merger due to the failure to obtain stockholder approval or failure to satisfy any other conditions to the completion of
the merger;
|
|
|
|
business uncertainty and contractual restrictions during the pendency of the merger;
|
|
|
|
the amount of the costs, fees, expenses and charges related to the merger;
|
|
|
|
diversion of managements attention from ongoing business concerns;
|
|
|
|
the effect of the announcement of the merger on our business, operating results and business relationships, including our ability to retain key
employees;
|
|
|
|
the possible adverse effect on our business and the price of our common stock if the merger is not completed in a timely manner or at all; and
|
|
|
|
other risks and uncertainties applicable to our business set forth in our filings with the Securities and Exchange Commission (SEC). See
Where You Can Find More Information beginning on page 75 of the proxy statement.
|
The
forward-looking statements are based on the information currently available and are applicable only as of the date on which the statements were made. Forward-looking statements involve known and unknown risks and uncertainties that may cause our
actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. You are urged to carefully review the disclosures we make in this supplement and the documents to which we refer you in
this supplement concerning risks and other factors that may affect us, including those made in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in our other reports filed with the SEC. The forward-looking
statements are qualified in their entirety by these cautionary statements, which are being made pursuant to the provisions of the Act and with the intention of obtaining the benefits of the safe harbor provisions of the Act. We caution
you that any forward-looking statements made in this supplement or the
9
documents to which we refer you in this supplement are not guarantees of future performance and that you should not place undue reliance on any of such forward-looking statements, which speak
only as of the date of this document. There may be additional risks of which we are presently unaware or that we currently deem immaterial. We do not intend, and undertake no obligation, to update our forward-looking statements to reflect future
events or circumstances, except as required by law.
Additional Information and Where to Find It
Investors and stockholders of Sun are urged to read the definitive proxy statement and other relevant documents because they contain
important information about the transaction. Copies of these documents may be obtained free of charge by making a request to Suns Investor Relations Department either in writing to Sun Healthcare Group, Inc., 18831 Von Karman, Suite 400,
Irvine, California 92612 or by telephone to (949) 255-7100. In addition, documents filed with the SEC by Sun may be obtained free of charge at the SECs website at www.sec.gov or at our website at sunh.com.
Sun and its directors, executive officers and certain employees may be deemed to be participants in the solicitation of proxies from
Suns stockholders in respect of the proposed transaction. Information concerning the ownership of Suns securities by Suns directors and executive officers is included in their SEC filings on Forms 3, 4 and 5, and additional
information is also available in Suns definitive proxy statement in connection with the proposed transaction.
10
Sun Healthcare (NASDAQ:SUNH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sun Healthcare (NASDAQ:SUNH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024